Ensysce Biosciences' chief operating officer resigns effective July 10, 2026
The company disclosed in a filing that Jeffrey Millard stepped down from the COO role, with the resignation taking effect the same day it was submitted.
Ensysce Biosciences, Inc. disclosed in a Form 8-K dated July 15, 2026 that the company received notice on July 10, 2026 that Jeffrey Millard was resigning from his post as Chief Operating Officer, with the resignation effective that same day.1
The filing was submitted under Item 5.02, which covers departures and appointments of officers and directors. It did not include additional detail on the reason for the departure, any severance arrangement, or a named successor.
The 8-K listed no other business items. Its only exhibit was a cover page interactive data file in Inline XBRL format, standard for such filings.
The document was signed on behalf of Ensysce Biosciences by Dr. Lynn Kirkpatrick, identified in the filing as the company's President and Chief Executive Officer. The filing is dated July 15, 2026.1
Ensysce Biosciences is registered with the SEC under commission file number 001-38306 and trades on Nasdaq under the ticker ENSC, per the filing's cover page. The company is incorporated in Delaware and lists its principal executive offices in La Jolla, California.
No further items, financial results, or strategic updates were included in this filing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.